Acute Leukemia – Relapsed/Refractory

- **Genetic mutation/target**
  - **CD33**
    - IRB# 15601: Phase 1 IMGN779 Intravenously
  - **Wild-Type TP53**
    - IRB# 16338: Phase 1/1b ALRN-6924 alone, in combination with Ara-C
    - Study Coming Soon: IRB# 19549
  - **MCL-1**
    - IRB# 7195: Phase 2 Kinase Inhibition, individualized targeted therapies

- **No specific mutation/target**
  - IRB# 17379: Phase 2 study of PDR001 and/or MBG453 in combination with decitabine
  - IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

- **Post-transplant**
  - IRB# 15993: HLA-A2.01 and PRAME
  - IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

**Studies Coming Soon for no specific mutation/target:**
- IRB# 15588 (SMMART Trial)
  - IRB# 18059
  - IRB# 19290
  - IRB# 19339
  - IRB# 19551

[Key]
- Open for Enrollment
- In Development
- Enrollment on Hold

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)

2/4/2019